• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novartis to cut 500 jobs in England

Novartis to cut 500 jobs in England

March 17, 2011
CenterWatch Staff

Novartis has announced plans to shed some 500 positions in the U.K. through an operational restructuring of its site in Horsham, West Sussex, England, according to PharmaTimes.

Currently, about 950 staff work at the Horsham campus, and that will fall to around 400 over the next two years. Novartis noted that of the workforce, about 330 are dedicated to respiratory research, which will remain in Horsham.

However, Basel, Switzerland-based Novartis said to "further align with global priorities," the gastrointestinal research teams at Horsham will be co-located with teams in Basel and Cambridge over one to two years, while Novartis U.K.'s over-the-counter operations will also move.

Novartis will maintain its major manufacturing sites in Grimsby, Liverpool and Dundee. The company said, "we are collaborating with the government on a number of valuable initiatives to promote life sciences research in the U.K., including Clinical Research Networks, the Academic Health Science Centres and the Therapeutic Capability Clusters."

As for the 500 jobs being lost, Novartis said proposals are currently under consultation and it could not give a final impact on staff numbers. Nevertheless, some observers see the plans as a blow to pharma in the U.K., especially after Pfizer's decision to close its R&D facility in Sandwich, Kent, cutting up to 2,400 jobs.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing